Blood Purification for the Treatment of Pathogen Associated Shock
Key facts
- Who runs it
- ExThera Medical Corporation
- Where
- Ann Arbor, Brunswick, Corvallis, Dallas, Langhorne, Rochester, San Antonio, and Washington D.C., United StatesSee the 9 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 15 people, planned
- Started
- 19 Apr 2024
- Expected to end
- 31 Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Seraph-100 + State of the Art Care
- State of the Art Care
- Record updated
- 14 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Admitted to an ICU with pathogen associated shock defined as:; The need for vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mmHg despite adequate fluid resuscitation, AND; Presence of a pathogen detected in the bloodstream within 72 hours of screening using commercially available in-vitro diagnostic testing
- Male or non-pregnant female adult
- At least 18 years of age at time of enrollment
Who cannot take part
- Inability to tolerate extracorporeal therapy (defined as MAP<65 despite fluids and vasopressors)
- Patients must be treated with one of the antimicrobial agents listed in the Antimicrobial Management Guideline (Table 19). Patients who require treatment with an antimicrobial outside of this list while still receiving treatment with the investigational device must be excluded from the study
- If a patient enters the study and later requires a change in the antimicrobial agent used to one which is not listed in the Antimicrobial Management Guideline while still receiving treatment with the investigational device, that patient must be removed from this trial. Clinical data for any patient removed from the trial for this reason will continue to be collected for safety evaluation"
- Advanced cancer (defined as stage IV) with life expectancy of less than 30 days
- Known allergy to heparin sodium
- High risk of bleeding (platelet count <50mm3 or International Normalized Ratio (INR) >2) unless adequate line for treatment already placed (e.g. ECMO or RRT/CRRT)
- Neutropenia with an absolute neutrophil count <500mm3
- Pregnant or breast feeding
- Anticipated transfer to another hospital (that is not a study site) within 72 hours for any reason
- Not anticipated to survive more than 24 hours
- Patients who cannot tolerate placement of double-lumen catheter
- Unable to obtain informed consent from either patient or legally authorized representative (LAR)
- Hypotension and volume depletion due to etiologies other than sepsis
- Patient is a prisoner or member of a different vulnerable population that should not be included in the study per the investigator or IRB/ethics committee
- Advanced directive for "Do Not Resuscitate"
Where in United States
- University of MichiganAnn Arbor, United States
- Southeast Georgia Health System, Inc.Brunswick, United States
- Good Samaritan HospitalCorvallis, United States
- University of Texas Southwestern Medical CenterDallas, United States
- Trinity Health Mid Atlantic-SMMCLanghorne, United States
- Mayo ClinicRochester, United States
- Methodist HospitalSan Antonio, United States
- University of Texas Health Science Center at San Antonio (UT Health San Antonio)San Antonio, United States
- George Washington UniversityWashington D.C., United States
About the trial
What the trial wants to find out
This study is a multi-center, randomized controlled feasibility trial to evaluate the initial safety and efficacy of a novel extracorporeal blood purification (EBP) therapy in critically ill patients with pathogen associated shock across 15 U.S. sites. Adults (18 years old and older) admitted to the ICU with all of the following:
Read full original descriptionShow less
• Pathogen associated shock defined as:
* The need for vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mmHg despite adequate fluid resuscitation * Presence of a pathogen detected in the bloodstream within 72 hours of screening using commercially available in-vitro diagnostic testing
The 2 groups in the trial
- 1- Seraph-100 plus State of the Art CareTreatment being tested
The Seraph 100 Filter is a single use, disposable column packed with ultra-high molecular weight polyethylene beads which have been modified to contain endpoint attached heparin on the surface. Seraph 100 is an extracorporeal broad-spectrum sorbent hemoperfusion device for reduction of pathogens from the bloodstream. It is intended for use with standard, commercially available bloodlines compatible with the pump system used. Female Luer connectors are required to connect to the Seraph 100 blood ports.
Treatment: Seraph-100 + State of the Art Care
- 2 - State of the Art CareExisting treatment, for comparison
"State of the Art care"is defined as the treatment algorithms outlined in the Surviving Sepsis Campaign for the treatment of septic shock, available at https://www.sccm.org/SurvivingSepsisCampaign/Home
Treatment: State of the Art Care
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Blood Purification for the Treatment of Critically Ill Patients With Pathogen Associated Shock: A Multicenter, Randomized Controlled Feasibility Trial
- Record updated
- 14 April 2026